Errett L, Walsh G
Can J Surg. 1986 May;29(3):214-5, 217.
Fibrin glue, although widely used in Europe for a decade, has not been commercially available in North America because its fibrinogen component is obtained from multiple, pooled, human blood donors with the subsequent increased risk of blood transmissible diseases. Techniques developed recently to isolate fibrinogen from single-donor plasma will circumvent these potential hazards. In Canada the use of fibrin glue has not been widespread even though biologic fibrin glue can be made from components readily available within most hospitals. Equal amounts of cryoprecipitate from fresh frozen plasma and bovine thrombin will combine within 2 minutes to form the fibrin glue. Simultaneous injections of each component at bleeding sites form a film of the glue that will effectively control even small arterial bleeding. The authors present three case reports to illustrate how use of the glue can save lives in cases of exsanguinating hemorrhage. They discuss the multiple applications of the fibrin glue which they believe will soon be part of the armamentarium of all Canadian surgeons.
纤维蛋白胶尽管在欧洲已广泛使用了十年,但在北美尚未商业化,因为其纤维蛋白原成分是从多个汇集的人类献血者中获取的,从而增加了血液传播疾病的风险。最近开发的从单供血者血浆中分离纤维蛋白原的技术将规避这些潜在风险。在加拿大,尽管大多数医院都能轻易获得制备生物纤维蛋白胶的成分,但纤维蛋白胶的使用并不广泛。等量的新鲜冷冻血浆冷沉淀和牛凝血酶在两分钟内会结合形成纤维蛋白胶。在出血部位同时注射每种成分会形成一层胶膜,即使是小动脉出血也能有效控制。作者给出了三个病例报告,以说明在大出血病例中使用这种胶水如何能挽救生命。他们讨论了纤维蛋白胶的多种应用,认为它很快将成为所有加拿大外科医生的装备之一。